Drug Trial Radar · NCT07158918
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Aug 6, 2025
Primary completion
Dec 2, 2027
Study completion Dec 2, 2027
Sponsor
- Lead sponsor
- ABL Bio, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
Conditions
- Solid Tumors
Interventions
ABL103Drug
IV infusion
KEYTRUDA® (pembrolizumab)Drug
IV infusion
TaxaneDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: Day 1 to Day 21 (Safety Lead-in Part 1) and Day 1 to Day 28 (Safety Lead-in Part 2)
- Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Related AEs, Serious AEs (SAEs), and Infusion-Related Reactions (IRRs)Time frame: From baseline through study completion, an average of 12 months
- Recommended Dose for Expansion (RDE) DeterminationTime frame: From baseline through study completion, an average of 12 months
- Objective Response Rate (ORR)Time frame: Up to approximately 30 months
- Disease Control Rate (DCR)Time frame: Up to approximately 30 months
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
UH Cleveland Medical Center
Cleveland, Ohio · Not yet recruiting
PASO Medical
Frankston, Victoria, Australia · Not yet recruiting
Seoul National University Bundang Hospital
Seongnam, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Not yet recruiting
Samsung Medical Center
Seoul, South Korea · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.